Old treatments for new genetic conditions: Sirolimus therapy in a child affected by mosaic overgrowth with fibroadipose hyperplasia

Clin Genet. 2019 Jul;96(1):102-103. doi: 10.1111/cge.13550. Epub 2019 Apr 22.

Abstract

PIK3CA-related overgrowth spectrum (PROS) are overgrowth diseases involving mesenchymal tissues caused by postzygotic variants in the PIK3CA gene. Fibro-Adipose hyperplasia or Overgrowth (FAO) belongs to PROS. We reported the beneficial effect of oral low-dose sirolimus therapy in a child affected by progressive FAO in term of stabilization of the disease, good tolerability, and easy management.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Absorptiometry, Photon
  • Adipose Tissue / abnormalities*
  • Child, Preschool
  • Fetal Macrosomia / diagnosis*
  • Fetal Macrosomia / drug therapy*
  • Fetal Macrosomia / genetics*
  • Genetic Predisposition to Disease*
  • Humans
  • Hyperplasia
  • Magnetic Resonance Imaging
  • Mosaicism*
  • Sirolimus / administration & dosage
  • Sirolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Sirolimus